Idiosyncratic drug hepatotoxicity

Nature Reviews Drug Discovery

Volumn 4, Issue 6, 2005, Pages 489-499

  Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALLOPURINOL; AMIODARONE; BOSENTAN; BROMFENAC; DANTROLENE; DICLOFENAC; DISULFIRAM; FELBAMATE; HALOTHANE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; ISOTRETINOIN; LABETALOL; LEFLUNOMIDE; METHYLDOPA; MINOCYCLINE; NEFAZODONE; NEVIRAPINE; NICOTINIC ACID; NITROFURANTOIN; PARACETAMOL; PEMOLINE; PHENOBARBITAL; PHENYTOIN; PYRAZINAMIDE; RIFAMPICIN; SULINDAC; TACRINE; TERBINAFINE; TOLCAPONE; TROGLITAZONE; TROVAFLOXACIN; VALPROIC ACID; XIMELAGATRAN; ZAFIRLUKAST; ZILEUTON;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ASTHMA; CELL DEATH; CHOLESTASIS; CHRONIC HEPATITIS; CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG COMPETITION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FATTY LIVER; GENETIC POLYMORPHISM; GOUT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTHESIS; INNATE IMMUNITY; JAUNDICE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER TUMOR; LIVER VENOOCCLUSIVE DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT MONITORING; PELIOSIS HEPATIS; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TUBERCULOSIS;

ANIMALS; HUMANS; LIVER; LIVER DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 20844444779     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1750     Document Type: Review

References (90)

1. Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Int. Med. 137, 947-954 (2002).
2. Kaplowitz, N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 24, 483-490 (2001).
3. Obermayer-Straub, P. & Manns, M. P. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 125-149 (Marcel Dekker, New York, 2003).
4. Maria, V. A. & Victorino, R. M. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug-induced liver injury. Gut 41, 534-540 (1997).
5. Maria, V. A. & Victorino, R. M. Immunological investigation in hepatic drug reactions. Clin. Exp. Allergy 28 (Suppl. 4), 71-77 (1998).
6. Gunawan, B. & Kaplowitz, N. Clinical perspectives in xenobiotic hepatotoxicity. Drug Metab. Rev. 36, 301-312 (2004).
7. Seguin, B. & Uetrecht, J. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 3, 235-242 (2003).
8. Touloukian, J. & Kaplowitz, N. Halothane-induced hepatic disease. Semin. Liver Dis. 1, 134-142 (1981).
9. Lewis, J. H. et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic corelations among 104 patients. Hepatology 9, 679-685 (1989).
10. Graham, D. J., Green, L., Senior, J. R. & Nourjah, P. Troglitazone-induced liver failure: a case study. Am. J. Med. 114, 299-306 (2003).
11. Tolman, K. G. Defining patient risks from expanded preventive therapies. Am. J. Cardiol. 86, 15E-19E (2000).
12. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
13. Njoku, D. B. et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Pediatr. Anesth. 94, 243-249 (2002).
14. Levy, M. Role of viral infections in the induction of adverse drug reactions. Drug Saf. 16, 1-8 (1997).
15. Ozick, L. A. et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am. J. Gastroenterol. 90, 1978-1980 (1995).
16. Wong, W.-M. et al. Antituberculous drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31, 201-206 (2000).
17. Ungo, J. R. et al. Antituberculous drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am. J. Respir. Crit Care Med. 157, 1871-1876 (1998).
18. Schwartz, G. G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 285, 1711-1718 (2001).
19. Kornbrust, D. J. et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J. Pharmacol. Exp. Ther. 248, 498-505 (1989).
20. Horsmans, Y., Desager, J. P. & Harvengt, C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol. Toxicol. 67, 336-339 (1990).
21. Senior, J. R. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 739-754 (Marcel Dekker, New York, 2003).
22. Zimmerman, H. J. in Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver (2nd edn) (ad. Zimmerman, H.) 433 (Lippincott, Philadelphia, 1999)
23. Chojkier, M. Troglitazone and liver injury: in search of answers. Hepatology 41, 237-246 (2005).
24. Menon, K., Angulo, P. & Lindor, K. D. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am. J. Gastroenterol. 96, 1631-1634 (2001).
25. Garcia-Rodriguez, L. A., Stricker, B. H. & Zimmerman, H. J. Risk of acute liver injury, associated with the combination of amoxicillin and clavulanic acid. Arch. Int. Med. 156, 1327-1332 (1996).
26. Stieger, B. et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118, 427-430 (2000).
27. Iverson, S. L. & Uetrecht, J. P. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem. Res. Toxicol. 14, 175-181 (2001).
28. Lakehal, F. et al. Indirect cytotoxicity of flucoxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol. 14, 694-701 (2001).
29. Dietrich, C. G., Ottenhoff, R., deWaart, D. R. & Oude Elferink, R. P J. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 167, 73-81 (2001).
30. Derby, L. E., Jick, H., Henry, D. A. & Dean, A. D. Erythromycin-associated cholestatic hepatitis. Med. J. Aust. 158, 600-602 (1993).
31. Selim, K. & Kaplowitz, N. Hepatotoxicity of psychotropic drugs. Hepatology 29, 1347-1351 (1999).
32. Andrade, R. J. et al. HLA Class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39, 1603-1612 (2004).
33. Watkins, P. B. & Whitcomb, R. W. Hepatic dysfunction associated with troglitazone. N. Eng. J. Med. 338, 916-917 (2001).
34. Watkins, P. B. et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271, 992-998 (1994).
35. Blackard, W. G., Sood, G. K., Cowe, D. R. & Fallon, M. B. Tacrine: a cause of fatal hepatotoxicity? J. Clin. Gastroenterol. 26, 57-59 (1998).
36. Lee, W. M. et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 28, 351-370 (2005).
37. Snider, D. E. & Caras, G. J. Isoniazid-associated hepatitis deaths: a review of available information. Am. Rev. Respir. Dis. 145, 494-497 (1992).
38. vanHest, R. et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin. Infect. Dis. 39, 488-496 (2004).
39. Willy, M. E. et al. A study of compliance with FDA recommendations for pemoline (Cylert). J. Am. Acad. Child Adolesc. Psychiatry 41, 785-790 (2002).
40. Graham, D. J. et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 286, 831-833 (2001).
41. Nolan, C. M., Goldberg, S. V. & Buskin, S. E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281, 1014-1018 (1999).
42. Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
43. Ulrich, R. G., Rockett, J. C., Gibson, G. G. & Pettit, S. D. Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. Environ. Health Perspect. 112, 423-427 (2004).
44. Mattes, W. B. et al. Database development in toxicogenomics: issues and efforts. Environ. Health Perspect. 112, 495-505 (2004).
45. Lindon, J. C. et al. Contemporary issues in toxicology: the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl Pharmacol. 187, 137-146 (2003).
46. Man, W. J. et al. Protein expression analysis of drug-mediated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2, 1577-1585 (2002).
47. Toyoda, Y., Tsuchida, A., Iwami, E. & Miwa, I. Toxic effect of troglitazone on cultured rat hepatocyles. Life Sci. 68, 1867-1876 (2001).
48. Tirmenstein, M. A. et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci. 69, 131-138 (2002).
49. Lloyd, S. et al. Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem. Biol Interact. 142, 57-71 (2002).
50. Shayiq, R. M. et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology 29, 451-463 (1999).
51. Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287-325 (Marcel Dekker, New York, 2003).
52. Lee, S. S. T. et al. Role of Cyp2e1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271, 12063-12067 (1996).
53. Burk, R. F., Hill, K. E., Hunt, R. W. & Martin, A. E. Isoniazid potentiation of acetaminophen hepatotoxicity in the rat and 4-methylpyrazole inhibition of it. Res. Commun. Chem. Pathol. Pharmacol. 69, 115-118 (1990).
54. Thummel, K. E. et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin. Pharm. Ther. 67, 591-599 (2000).
55. Chien, J. Y., Thummel, K. E. & Slattery J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165-1175 (1997).
56. Goldring, C. E. P. et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 39, 1267-1276 (2004).
57. Chan, K., Han, X.-D. & Kan, Y. W. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl Acad. Sci. USA 98, 4611-4616 (2001).
58. Ishida, Y. et al. A pivotal involvement if IFN-γ in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J. 16, 1227-1236 (2002).
59. Liu, Z.-X., Govindarajan, S. & Kaplowitz, N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127, 1760-1774 (2004).
60. Bourdi, M. et al. Protection against acetaminophen induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35, 289-298 (2002).
61. Masubuchi. Y. et al. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun. 304, 207-212 (2003).
62. Kaplowitz, N. Acetaminophen hepatotoxicity: what we know, what we don't know and where do we go? Hepatology 40, 23-26 (2004).
63. Nagai, H., Matsumaru, K., Feng, G. & Kaplowitz, N. Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-α-induced apoptosis in cultured mouse hepatocytes. Hepatology 36, 55-64 (2002).
64. Kaplowitz, N. Mechanisms of liver cell injury. J. Hepatol. 32, 39-47 (2000).
65. Park, D. R. et al. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macro-phages. J. Immunol. 170, 6209-6216 (2003).
66. Hohlbaum, A. M., Gregory, M. S., Ju, S. T. & Marshak-Rothstein, A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167, 6217-6224 (2001).
67. Liu, Z.-X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467-486 (Elsevier, 2002).
68. Kaplowitz, N. in Seminars in Liver Disease Vol. 22 (eds Berk, P., Farrell, G. & Liddle, C.) 137-144 (Thieme Medical, New York, 2002).
69. Vergani, D. et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Eng. J. Med. 303, 66-71 (1980).
70. Neuberger, J. & Williams, R. Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 30, 515-519 (1989).
71. Kon, K., Kim, J.-S., Jaeschke, H. & Lemasters, J. J. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 40, 1170-1179 (2004).
72. Watanabe, I. et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharm. Ther. 73, 435-455 (2003).
73. Simon, T. et al. Combined glutathione S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharm. Ther. 67, 432-437 (2000).
74. Acuna, G. et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. The Pharmacogenomics J. 2, 327-334 (2002).
75. Huang, Y.-S. et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculous drug-induced hepatitis. Hepatology 37, 924-930 (2003).
76. Aithal, G. P. et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430-1440 (2004).
77. Zhang, J. et al. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298, 421-424 (2002).
78. Henderson, C. J. et al. Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc. Natl Acad. Sci. USA 97, 12741-12745 (2000).
79. Zhang, H. et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nature Biotechnol. 18, 862-867 (2000).
80. Bone-Larson, C. L. et al. IFN-γ-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes. J. Immunol. 167, 7077-7083 (2001).
81. Hogaboam, C. M. et al. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines. FASEB J. 13, 1565-1574 (1999).
82. Trepicchio, W. L., Bozza, M., Bouchard, P. & Dorner, A. J. Protective effect of rhIL-11 in a murine model of acetaminophen-induced hepatotoxicity. Toxicol. Pathol. 29, 242-249 (2001).
83. Su, G. L. et al. Lipopolysaccharide-binding protein modulates acetaminophen-induced liver injury in mice. Hepatology 41, 187-195 (2005).
84. Jollow, D. J. et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 187, 195-202 (1973).
85. Reilly, T. P. et al. A protective role for cycloxygenase-2 in drug-induced liver injury in mice. Chem. Res. Toxicol. 14, 1620-1628 (2001).
86. Ju, C. et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem. Res. Toxicol. 15, 1504-1513 (2002).
87. Hogaboam, C. M. et al. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am. J. Pathol. 156, 1245-1252 (2000).
88. Hogaboam, C. M. et al. Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury. Gene Ther. 6, 573-584 (1999).
89. Tinel, M. et al. Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice. Hepatology 39, 655-666 (2004).
90. Matsumaru, K., Ji, C. & Kaplowitz, N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology 37, 1425-1434 (2003).